JC JOINT Corp Stock: price and management transactions · United States · SEC (Form 4)Follow the JOINT Corp share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, JOINT Corp has logged 51 insider filings. Market capitalisation: €119.4m. The latest transaction was reported on 22 May 2026 (Attribution). Among the most active insiders: Bandera Partners LLC. Every trade is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 13,746 of 29,065 companies
FCF yld 0.3%
Earn yld 2.4%
EV/EBITDA ·
ROE 11%
Gross mgn 80%
Net mgn 5.3%
Debt/EBITDA 2.5x
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 22 May 2026
All Executives51 Thresholds0 Prospectus0 Other0
Declarations 51 total
◆ Director · Executives · 20 May 2026
5,714 shares 0Common Stock SEC:0001622400-26-000005:0
▲ 10% Owner · Executives · 21 Apr 2026
509 shares @ US$8.58 0.0033% mcap 0.4% of flow Common SEC:0001214659-26-005023:0
Canonical exit: 20 Jul 2026 (T+90) ◆ Director · Executives · 21 May 2025
4,995 shares 0Common Stock SEC:0000950170-25-077116:0
◆ Director · Executives · 21 May 2025
4,995 shares 0Common Stock SEC:0000950170-25-077101:0
◆ Director · Executives · 21 May 2025
4,995 shares 0Common Stock SEC:0000950170-25-077108:0
◆ Director · Executives · 21 May 2025
4,995 shares 0Common Stock SEC:0000950170-25-077098:0
◆ Chief Financial Officer · Executives · 10 Mar 2025
15,936 shares 0Common Stock SEC:0000950170-25-038267:0
◆ See Remarks · Executives · 10 Mar 2025
50,973 shares 0Common Stock SEC:0000950170-25-038265:0
◆ See Remarks · Executives · 14 Oct 2024
38,059 shares 0Common Stock SEC:0000950170-24-115056:0
◆ Chief Financial Officer · Executives · 4 Mar 2024
17,874 shares 0Common Stock SEC:0000950170-24-064660:0
◆ Director · Executives · 22 May 2024
2,958 shares 0Common Stock SEC:0000950170-24-064677:0
◆ Director · Executives · 22 May 2024
2,958 shares 0Common Stock SEC:0000950170-24-064686:0
◆ Director · Executives · 22 May 2024
2,958 shares 0Common Stock SEC:0000950170-24-064696:0
◆ Director · Executives · 22 May 2024
2,958 shares 0Common Stock SEC:0000950170-24-064709:0
◆ Director · Executives · 22 May 2024
2,958 shares 0Common Stock SEC:0000950170-24-064673:0
◆ President and CEO · Executives · 4 Mar 2024
29,103 shares 0Common Stock SEC:0000950170-24-064667:0
95 shares @ US$9.40 0.0% of flow Common Stock, $0.001 Par Value Per Share SEC:0000921895-23-002207:0
Canonical exit: 18 Dec 2023 (T+90) 21,381 shares @ US$8.9433 3.6% of flow Common Stock, $0.001 Par Value Per Share SEC:0000921895-23-002188:0
Canonical exit: 13 Dec 2023 (T+90) 8,276 shares @ US$9.4257 1.2% of flow Common Stock, $0.001 Par Value Per Share SEC:0000921895-23-002156:0
Canonical exit: 10 Dec 2023 (T+90) 4,480 shares @ US$9.1013 0.6% of flow Common Stock, $0.001 Par Value Per Share SEC:0000921895-23-002138:0
Canonical exit: 4 Dec 2023 (T+90) 6,247 shares @ US$9.5289 0.9% of flow Common Stock, $0.001 Par Value Per Share SEC:0000921895-23-002088:0
Canonical exit: 21 Nov 2023 (T+90) 3,903 shares @ US$12.9218 0.8% of flow Common Stock, $0.001 Par Value Per Share SEC:0000921895-23-001994:0
Canonical exit: 7 Nov 2023 (T+90) 125,410 shares @ US$12.9305 24.6% of flow Common Stock, $0.001 Par Value Per Share SEC:0000921895-23-001911:0
Canonical exit: 7 Nov 2023 (T+90) 22,164 shares @ US$13.0325 4.3% of flow Common Stock, $0.001 Par Value Per Share SEC:0000921895-23-001692:0
Canonical exit: 12 Oct 2023 (T+90) ▲ 10% Owner · Executives · 17 Jul 2023
299 shares @ US$13.10 0.1% of flow Common Stock, $0.001 Par Value Per Share SEC:0000921895-23-001692:1
Canonical exit: 15 Oct 2023 (T+90) 25 of 51 declarations
Load more (26 remaining) 关于 JOINT Corp The Joint Corp. (NASDAQ: JYNT) 是一家在美国纳斯达克市场上市的美国医疗保健服务公司。其核心业务是在 The Joint Chiropractic® 品牌下开发、特许经营和运营脊椎治疗诊所。该公司成立于 2010 年 3 月 10 日,旨在通过特许经营主导模式建立脊椎治疗诊所网络,同时有时也运营少量公司自有或管理的诊所。其总部位于美国亚利桑那州斯科茨代尔。
从投资角度来看,The Joint Corp. 定位为一个专注于便利性、可及性和标准化服务交付的零售医疗保健平台。该公司的模式强调无需预约的脊椎治疗护理和对消费者友好的价格点,管理层称其低于许多竞争对手同类服务的定价,并且通常低于典型的保险共付额水平。这使得该业务更类似于一个品牌化的本地医疗保健网络,而非一个严重依赖报销的传统提供商。对于讲法语的投资者而言,其吸引力在于经常性特许经营经济效益、品牌认知度和潜在可扩展的业务范围的结合。
The Joint Corp. 的竞争优势来自于其标准化的诊所形式、庞大且不断扩张的特许经营系统以及简化的消费者价值主张。该公司报告在美国多个州开展业务,包括阿肯色州、加利福尼亚州、科罗拉多州、佛罗里达州、伊利诺伊州、马里兰州、密歇根州、新泽西州、纽约州、北卡罗来纳州、俄勒冈州、宾夕法尼亚州、田纳西州、华盛顿州等。虽然其地理范围是全国性的,但业务仍集中在美国,这降低了国际复杂性,但将业绩与国内消费者趋势和本地诊所执行情况挂钩。
近期发展集中在再特许经营和投资组合简化。管理层一直在出售某些公司自有或管理的诊所,并将资源重新导向更侧重特许经营的结构,以提高盈利能力并降低运营复杂性。在 2025 年初和 2026 年春季,该公司再次强调了旨在加强核心业务、收紧成本和改善同诊所业绩的举措。因此,The Joint Corp. 仍然是一个小盘股消费医疗保健特许经营故事,其关键投资驱动因素包括执行质量、特许经营增长、同店销售趋势以及管理层将重组转化为可持续现金流的速度。